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in an increase in 20S and 26S proteasome 
activity under certain atrophy-inducing 
conditions. These new data suggest that 
the in vivo targets of MuRF1 may not be 
restricted to the thick filament proteins, 
and suggest possible roles in transcription 
and protein synthesis.
Dr. Kandarian presented data on 
NF-kappaB signaling in skeletal muscle 
atrophy. The transcription factors p50 and 
Bcl-3 are required for hind limb unload-
ing induced muscle atrophy and unloading 
induced activation of NF-kappaB reporter 
activity. That is, NF-kappaB activity is 
abolished and fiber atrophy completely 
prevented in unloaded muscle in mice 
lacking p50 or Bcl-3. To understand the 
cellular regulation of disuse atrophy Dr. 
Kandarian’s laboratory identified down-
stream target genes of p50 and Bcl-3 
transcription factors using global gene 
expression microarrays in wild type and 
knockout mice for these two factors. All 
genes identified as p50 target genes were a 
subset of the genes identified as Bcl-3 target 
genes, suggesting they may act together in 
regulating gene expression during muscle 
atrophy. In order to identify genes that have 
increased Bcl-3 binding on a genome-wide 
basis and thus are Bcl-3 direct downstream 
target genes during atrophy, Dr. Kandarian 
used ChIP-sequencing on chromatin iso-
lated from control and 5 day unloaded 
muscle. Compared to control, there was 
increased Bcl-3 binding in unloaded mus-
cle in families of genes that regulate prote-
olysis, while p50 binding was often found 
in the same gene locations but to a similar 
extent in control and unloaded muscle. Dr. 
Kandarian summarized that, as the trans-
activator in p50-Bcl-3 complexes, Bcl-3 
atrophy that accompanies numerous 
chronic disease states, it should come as no 
surprise that a major focus of this meet-
ing was on fundamental aspects of mus-
cle mass regulation. At its roots, skeletal 
muscle mass is determined by the constant 
interplay between mechanisms that drive 
protein synthesis vs. those that promote 
protein degradation. The first and larg-
est session of this meeting thus included 
presentations by 11 scientists prominent 
in the field of muscle mass regulation who 
have taken advantage of animal models to 
reveal key cellular and molecular mecha-
nisms that mediate muscle atrophy and 
hypertrophy. These speakers included Drs. 
Sue Bodine, Susan Kandarian, Andrew 
Judge, Charlotte Peterson, Yi-Ping Li, 
Teresa Zimmers, Jim Carson, Mike Reid, 
Zhen Yan, Scott Powers, and Esther 
Dupont-Versteegden.
Like all other sessions, these speakers 
described the current state of knowledge 
in specific niches while highlighting their 
findings and contributions to the field. A 
few of these presentations are highlighted 
here. For example, Dr. Bodine opened 
the symposium by presenting her work 
on the role of MuRF1 in skeletal muscle 
atrophy. MuRF1 and MAFbx were identi-
fied in 2001 as atrophy-associated genes. 
In the past 10 years, both genes have been 
shown to be upregulated under a variety 
of atrophy-inducing conditions. Data were 
presented showing that deletion of MuRF1, 
but not MAFbx, results in muscle sparing 
under a variety of atrophy-inducing con-
ditions. Further, inhibition of MAFbx was 
not required to get muscle sparing in the 
MuRF1 KO mice. Contrary to what has 
been predicted, deletion of MuRF1 resulted 
The “Advances in Skeletal Muscle Biology in 
Health and Disease” conference was held in 
Gainesville, Florida February 22nd to 24th 
2012. The primary purpose of this meeting 
was to facilitate advances in adult skeletal 
muscle biology and physiology. There were 
210 registered participants from 64 different 
institutions and 4 pharmaceutical compa-
nies, including participants from 10 differ-
ent countries. Approximately 40% of the 
attendees and one-third of the symposium 
speakers were women. The meeting began 
with a grant writing workshop that included 
an overview of training grants, R01 grant 
structure, and grants scoring and interpret-
ing reviewer comments given by Drs. Tom 
Clanton, Denis Guttridge, Marcas Bamman, 
and Sue Bodine. This workshop was followed 
by a poster session that included 65 outstand-
ing posters presented by faculty, postdoctoral 
fellows, and graduate students. The sympo-
sium consisted of 28 total speakers across four 
main sessions. In this two part synopsis we 
outline some of the main findings, current 
paradigms, and future directions presented 
in each of these sessions. In Part 1, we out-
line Day 1 of the symposium which consisted 
of sessions on “Cell signaling mechanisms 
mediating muscle atrophy and hypertrophy” 
and “Muscle force, calcium handling, and 
stress response.” In Part 2, we outline Day 2 
of the symposium which consisted of sessions 
on “Muscle diseases and regeneration” and 
“Clinical/translational research.”
Cell signaling meChanisms 
mediating musCle atrophy and 
hypertrophy
Considering the powerful impact of skel-
etal muscle mass on health status, and the 
deleterious consequences of the  muscle 
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Westerblad, Leonardo Ferreira, and Tom 
Clanton. Dr. Westerblad presented work 
from his laboratory showing that Ca2+ 
plays an important role in the interaction 
between mitochondria and general skeletal 
muscle cell function. The concentration and 
location of Ca2+ is critical for the physio-
logical effects. Indeed, findings from the 
Westerblad laboratory show that a limited 
Ca2+ leak from the sarcoplasmic reticulum 
(SR) is accompanied by increased mito-
chondrial biogenesis and increased fatigue 
resistance, whereas a larger SR Ca2+ leak 
results in muscle weakness. On the other 
hand, muscle fibers of mice with a specific 
mitochondrial myopathy accumulate Ca2+ 
in the mitochondria, which is accompanied 
by decreased SR Ca2+ content and muscle 
weakness. These complex Ca2+-dependent 
interactions were discussed.
Dr. Ferreira presented his work on 
sphingolipids, oxidants, and skeletal mus-
cle contractile dysfunction in heart failure. 
Sphingomyelinase (SMase) catalyzes the 
conversion of sphingomyelin to ceramide 
and phosphorylcholine. Ceramide acts as 
a second messenger that activates various 
signaling pathways and increases oxidants 
in the cell. SMase activity is heightened in 
patients with congestive heart failure (CHF) 
and is inversely related to skeletal muscle 
force. Dr. Ferreira presented preliminary 
data suggesting that SMase activity and cer-
amide content are heightened in the skeletal 
muscle of CHF rats. Exogenous exposure 
of intact skeletal muscle to SMase in vitro 
decreases force and this effect is prevented 
by antioxidants. The decrease in force elic-
ited by SMase was also evident in skinned 
single fibers, which showed lower maximal 
force and calcium sensitivity of the con-
tractile apparatus. Dr. Ferreira concluded 
that SMase and ceramide promote oxidant-
mediated muscle weakness. Thus, increased 
SMase activity and ceramide content may 
contribute to contractile dysfunction in 
CHF.
The first day ended with an informal 
dinner, attended by 176 of the registrants, 
where friendly scientific discussions on 
adult muscle plasticity continued through-
out the evening.
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and in vivo. Inhibition of STAT3 by  various 
mechanisms reduced muscle wasting in 
conditions of high IL-6 or cancer.
Dr. Yan presented evidence that in vivo 
administration of the endogenous NO 
donor, S-Nitroso-l-glutathione, induces 
Extracellular Superoxide Dismutase 
(EcSOD) expression and provides protec-
tion against dexamethasone-induced mus-
cle atrophy. Both somatic gene transfer of 
EcSOD and transgenic overexpression of 
EcSOD are sufficient to render protection 
against catabolic muscle wasting. Dr. Yan 
also presented evidence that muscle-derived 
EcSOD expression in transgenic mice pro-
vides profound protection against multi-
ple organ dysfunction syndrome (MODS) 
induced by endotoxemia.
Dr. Dupont-Versteegden presented 
her recent data showing failed muscle re-
growth in the muscles of old vs. young rats. 
Specifically, the soleus muscle of 6- and 
32-month-old rats atrophied in response to 
2 weeks of hind limb suspension but only 
muscles from the 6 month old returned to 
control levels following 2 weeks of reload-
ing. mRNA abundance of protein degrada-
tion marker MAFbx and autophagy markers 
Atg5 and Atg7 increased with hind limb sus-
pension and were restored to control with 
reloading in soleus muscle of young and old 
rats. Similarly, phosphorylated GSK3beta 
was decreased with atrophy and returned 
to control upon reloading in both ages. In 
contrast, no changes in phosphorylated 
p70s6 kinase were observed at either age. 
Dr. Dupont-Versteegden concluded that 
changes in anabolic and catabolic pathways 
associated with alterations in muscle size 
are similar in soleus muscles of young and 
old rats, suggesting that factors external to 
muscle may play a role in the attenuated 
muscle re-growth response in the aged.
musCle forCe, CalCium handling, 
and stress response
Beyond its mass, the force generating capac-
ity of skeletal muscle is highly dependent 
on, among other factors, the integrity of 
the excitation-contraction coupling sys-
tem and mitochondrial function. Recent 
advances of molecular biology and imaging 
technologies have markedly expanded our 
understanding of these critical modulators 
of muscle force. The presentations of the 
second session therefore highlighted recent 
contributions to this field by Drs. Håkan 
binding to target genes found in  atrophying 
muscle further supports its role as an essen-
tial regulator of the genes causing muscle 
atrophy due to disuse.
Dr. Peterson discussed and presented 
data to show that in satellite cell-depleted 
mouse muscle, robust fiber hypertrophy, 
and re-growth following atrophy occur 
independent of myonuclear accretion. 
These novel findings challenge the pop-
ular view that myofiber hypertrophy is 
facilitated by, or dependent upon, satel-
lite cell-mediated myonuclear addition. 
Further, the results indicate no other cell 
population is replacing satellite cells in 
this myonuclear addition role. However, 
muscle regeneration is impaired in satellite 
cell-depleted mouse muscle, showing that 
muscle fiber regeneration and hypertrophy 
have distinct satellite cell requirements. Dr. 
Peterson concluded by posing some open 
questions for discussion, including “Can 
the mechanisms that enable mouse muscle 
to grow in the absence of satellite cells be 
activated in human muscle as therapeutic 
targets for sarcopenia, cachexia, or mus-
cle wasting?” “Are there species-specific 
differences in the flexibility of the myo-
nuclear domain?” and, “Are there techni-
cal limitations to quantification of satellite 
cell fusion/myonuclear dynamics in adult 
muscle?”
Dr. Li presented his findings showing 
that Lewis lung carcinoma cells release 
soluble factors which induce ubiquitin 
ligase atrogin1/MAFbx upregulation and 
muscle catabolism. Carcinoma-induced 
atrogin1/MAFbx upregulation is medi-
ated by p38β MAPK activation of tran-
scription factor C/EBPβ binding to the 
atrogin1/MAFbx promoter via selective 
phosphorylation, and is independent of 
FoxO1/3. Further, muscle wasting induced 
by tumor xenograft is blocked in C/EBPβ 
null mice or mice administered an inhibi-
tor of p38α/β MAPK. Dr. Li concluded that 
the p38β MAPK-C/EBPβ signaling path-
way appears to be a therapeutic target for 
cancer cachexia.
Dr. Zimmers also presented data on can-
cer cachexia and began by emphasizing that 
although IL-6 and related ligands have been 
implicated in muscle wasting of cancer, the 
downstream signaling pathways responsible 
are unknown. Dr. Zimmers subsequently 
presented data indicating that STAT3 is 
causally involved in muscle wasting in vitro 
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